
On August 16, 2026, Shanghai UnicornShell Pharmaceutical Technology Co., Ltd. and the China-Pakistan International Commercial Alliance (PCCAI) held a strategic cooperation signing ceremony in Xi'an. The partnership marks a substantive step in UnicornShell's industrial layout under the China-Pakistan Economic Corridor framework and officially launches a new chapter for China's intelligent manufacturing of plant-based capsules to go global.
01
Project Overview
The 1-billion-capacity plant-based capsule project under the China-Pakistan alliance was signed by PCCAI, Shanghai UnicornShell Pharmaceutical Technology Co., Ltd., Shaanxi Ximei UnicornShell Pharmaceutical Technology Co., Ltd., and Hainan Baitao Investment Co., Ltd. The agreement was signed on behalf of the parties by Wang Yongxin, Chairman of PCCAI; Lu Wei, Co-founder of Shanghai UnicornShell; Zhao Songjiang, Chairman of Shaanxi Ximei UnicornShell; and Zhang Bingsheng, Chairman of Hainan Baitao Investment.
Drawing on their respective resource strengths and UnicornShell's 27 years of expertise in plant-based capsules, the parties will build a plant-based pharmaceutical excipient cooperation platform serving the China-Pakistan Economic Corridor.
More than 50 government and business guests attended the signing ceremony, including renowned economist Jin Qiansheng; Liu Haochun, Party Secretary and Chairman of the Shaanxi-Jiangsu Western-Eastern Cooperation and Development Promotion Association; Li Xinfang, President of the Shaanxi Traditional Chinese Medicine Science and Technology Innovation Research Association; Ma Chuan, Shaanxi Provincial People's Congress deputy, member of the Shaanxi Provincial Government Decision-Making Advisory Committee, and Publisher-in-Chief of Times Figure magazine; and Meng Zhiliang, member of the Party Committee and Deputy General Manager of Shenmu State-owned Capital Investment Operation Group.
02
Supporting the Belt and Road Initiative and Industrial Globalization
China and Pakistan are close neighbors with iron-clad friendship that has grown stronger over 75 years of diplomatic relations. In May 2026, the leaders of the two countries jointly announced the high-quality development of the "China-Pakistan Economic Corridor 2.0 Upgrade," opening broader opportunities for enterprises to expand overseas.
UnicornShell's cooperation with PCCAI is a concrete action by China's plant-based capsule intelligent-manufacturing enterprise to support the Belt and Road Initiative and pursue industrial globalization.
03
UnicornShell's Track Record in Plant-Based Capsules
Since launching plant empty capsule R&D in 1999, UnicornShell has spent 27 years on one mission: making plant-based capsules another name card of Chinese intelligent manufacturing. The company has secured more than 30 domestic and international patents covering formulations, processes, equipment, and supporting manufacturing environments, and has built a complete IP protection system combining patents, proprietary technologies, and software copyrights. Its proprietary process, paired with fully servo-driven intelligent production lines, creates a digital quality-control model integrating "formulation, equipment, process, and environment," with a 99.99% machine-feeding qualification rate.
UnicornShell's products have completed U.S. FDA registration, Halal certification, European BRCGS certification, and China NMPA drug master-file/associated review in 2023, and are sold in global markets. The cooperation with PCCAI will combine UnicornShell's R&D, manufacturing, and quality-control capabilities with the potential needs of Pakistan's pharmaceutical and healthcare market of 240 million people, helping localize supply and raise quality standards for pharmaceutical excipients.
04
Overseas Commitment
UnicornShell's management stated that its globalization is not simply product export, but joint development of technology, standards, and production capacity. The company commits to:


